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The aim of this study was to examine mutations in the quinolone-resistance-determining
region (QRDR) of gyrA and parC genes in Pseudomonas aeruginosa isolates. A total of 100
clinical P. aeruginosa isolates were collected from different university-afﬁliated hospitals
in  Tabriz, Iran. Minimum inhibitory concentrations (MICs) of ciproﬂoxacin and levoﬂoxacin
were evaluated by agar dilution assay. DNA sequences of the QRDR of gyrA and parC were
determined by the dideoxy chain termination method. Of the total 100 isolates, 64 were
resistant to ciproﬂoxacin. No amino acid alterations were detected in gyrA or parC genes of
the  ciproﬂoxacin susceptible or ciproﬂoxacin intermediate isolates. Thr-83 → Ile substitu-
tion  in gyrA was found in all 64 ciproﬂoxacin resistant isolates. Forty-four (68.75%) of them
had additional substitution in parC. A correlation was found between the number of the
amino acid alterations in the QRDR of gyrA and parC and the level of ciproﬂoxacin and levo-
ﬂoxacin resistance of the P. aeruginosa isolates. Ala-88 → Pro alteration in parC was generally
found in high level ciproﬂoxacin resistant isolates, which were suggested to be responsible
for ﬂuoroquinolone resistance. These ﬁndings showed that in P. aeruginosa, gyrA was the
primary target for ﬂuoroquinolone and additional mutation in parC led to highly resistant
isolates.
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Introduction
Pseudomonas aeruginosa is an important opportunistic
pathogen1–3 causing life-threatening infections, especially in
immunocompromised patients.4–6 Often these infections are
difﬁcult to treat due to the intrinsic resistance of the species7
as well as its remarkable ability to acquire resistance to a
wide range of antimicrobial agents.8 Fluoroquinolones are
the only accessible antibiotics for effective oral treatment
of infections caused by this organism.9 Among ﬂuoro-
quinolones, ciproﬂoxacin and levoﬂoxacin are widely used in
the treatment of P. aeruginosa infections.10
Fluoroquinolones act by inhibiting the action of tar-
get enzymes, DNA gyrase and topoisomerase IV, with both
enzymes playing a principal role in DNA replication.11 DNA
gyrase and topoisomerase IV are heterotetrameric enzymes
that are composed of two subunits encoded by the gyrA, gyrB
and parC, parE, respectively.12 The gyrA and gyrB genes are
homologs to parC and parE, respectively.13 The mechanisms of
ﬂuoroquinolone resistance in P. aeruginosa include mutations
in the DNA gyrase and topoisomerase IV,14,15 overexpress-
ion of efﬂux pump system and the innate impermeability
of the membrane.16 Alterations in the so-called quinolone-
resistance-determining region (QRDR) within DNA gyrase
and topoisomerase IV are the major mechanisms for ﬂuoro-
quinolone resistance in P. aeruginosa.17–20
Moreover, isolates with mutations in QRDR of gyrA and
parC show the highest levels of ﬂuoroquinolone resistance.21
Although amino acid alterations in the gyrB and parE genes
have been described, but the frequency of these mutations
is low, with only a complementary role in ﬂuoroquinolone
resistance.18,21
Several studies from Iran have reported the high prevalence
of MDR  strains among Iranian hospitals and strains isolated
from hospitalized patients; especially, burn patients have
show high level resistance to most available antibiotics.22,23
The prevalence of mutations in DNA gyrase and topoi-
somerase IV has not been well studied in Iran. This is
Table 1 – Distribution of Pseudomonas aeruginosa isolates by the
Source of isolates Hospital  o
Imam Reza Sina K
Tracheal aspirate 7 4 
Wound discharge 7 8 
Urine 7 6 
Blood 1 4 
Throat culture 1 0 
Catheter 0 0 
Sputum 0 1 
Bronchial washing 0 0 
Pleural ﬂuid culture 1 0 
Urethral discharge 1 0 
Peritoneal ﬂuid 1 0 
Ear discharge 0 1 
Stool 1 0 
Total 27 24  b i o l o g y 4 7 (2 0 1 6) 925–930
the largest analysis of the QRDR of gyrA and parC in the
clinical isolates of P. aeruginosa from Iran. The aim of this
study was to examine the mutations in gyrA and parC genes
and characterize their correlation with ciproﬂoxacin and
levoﬂoxacin resistance, as well as the evaluation of their
effect on ciproﬂoxacin and levoﬂoxacin Minimum inhibitory
concentrations (MICs) among the clinical isolates of P. aerugin-
osa.
Materials  and  methods
Bacterial  isolates
In a prospective study, a total of 100 non-repetitive clinical
isolates of P. aeruginosa were collected, between December
2013, and July 2014, from four Educational-Health Care Cen-
ters of Tabriz University of Medical Sciences in Northwest Iran.
The bacterial isolates were recovered from different clinical
specimens such as urine (29%), wound discharge (25%), tra-
cheal aspirates (21%), blood (8%) and other clinical specimens
(Table 1). All isolates were identiﬁed by standard conventional
biochemical tests.24
Antimicrobial  susceptibility  testing
Antimicrobial susceptibility to ticarcillin (75 g), piperacillin-
tazobactam (100/10 g), ceftazidime (30 g), cefepime (30 g),
aztreonam (30 g), imipenem (10 g), meropenem (10 g),
gentamicin (10 g), amikacin (30 g), ciproﬂoxacin (5 g),
levoﬂoxacin (5 g) and oﬂoxacin (5 g) (Mast, UK) was per-
formed by employing the standard disk diffusion method.
MICs of ciproﬂoxacin and levoﬂoxacin (Sigma-Aldrich) were
determined by the standard agar dilution assay. The
results of disk diffusion assay as well as MIC  were inter-
preted according to the clinical and laboratory standard
institute (CLSI) guidelines.25 Pseudomonas aeruginosa ATCC
27853 was used as the control strain for susceptibility
testing.
 site of isolation and hospital origin.
rigin Total no. of isolates
oodakan Shahid Madani
6 4 21
4 6 25
9 7 29
1 2 8
3 0 4
2 2 4
1 0 2
0 2 2
0 0 1
0 0 1
0 0 1
0 0 1
0 0 1
26 23 100
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Table 2 – Amino acid alterations in gyrA and parC in ciproﬂoxacin resistant isolates of Pseudomonas aeruginosa.
Groups No.  of isolates Replacement in QRDR
GyrA at position ParC at position
83 87 87 88
PAO1 Thr (ACC) Asp (GAC) Ser (TCG) Ala (GCC)
I 20 Ile (ATC) – – –
II 8 Ile (ATC) – – Pro (CCC)
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aIII 31 Ile (ATC) 
IV 5 Ile (ATC) 
CR  ampliﬁcation  and  DNA  sequencing
hromosomal DNA from the isolates of P. aeruginosa was
xtracted by DNA extraction kit (Yekta Tajhiz Azma, Iran)
ccording to the manufacturer’s instructions. The PCR reac-
ion was performed in a 50 L mixture containing 1.5 mM
gCl2, 0.5 pmol of each primer, 0.2 mM dNTPs (Yekta Tajhiz
zma, Iran), 1U of Pfu DNA polymerase (Yekta Tajhiz Azma,
ran), 1X Pfu DNA polymerase buffer and 10–100 ng of the tem-
late DNA.
The ampliﬁcation of gyrA and parC genes was carried
ut using the polymerase chain reaction and speciﬁc primer
ets as described previously.26 Puriﬁed PCR products were
equenced using the Applied Biosystems 3730/3730xl DNA
nalyzers sequencing (ABI) system, (Bioneer Co., Korea).
tatistical  analysis
ategorical variables were compared by the Chi-square test
r Fisher’s exact test using SPSS 16.0 statistical software (SPSS
nc., Chicago, IL). A statistically signiﬁcant difference was con-
idered as a P-value < 0.05.
esults
ntimicrobial  susceptibility  testing
f the 100 P. aeruginosa clinical isolates tested for antimicro-
ial susceptibility, 71 of them were found to show multidrug
esistance (MDR). MDR  was deﬁned as resistance to three or
ore  unrelated antibiotics.27 The highest rate of resistance
as observed against ticarcillin (84%) and oﬂoxacin (82%).
oreover, the highest susceptibility rate was obtained against
eftazidime (45%), followed by gentamicin (44%). Of the total
solates, 64 (64%) were resistant, 2 (2%) were intermediate
nd 34 (34%) were observed to be susceptible to ciproﬂoxacin.
oreover, 63% of isolates were resistant, 1% were intermedi-
te, and 36% were susceptible to levoﬂoxacin.
NA  sequences  analysis
NA sequences of all P. aeruginosa isolates were compared with
he corresponding sequences of P. aeruginosa PAO1 (Accession:
C 002516.2 GI: 110645304). Aside from ciproﬂoxacin suscep-ible, levoﬂoxacin susceptible and ciproﬂoxacin intermediate
solates which had no amino acid alterations in their gyrA or
arC genes, the amino acid alterations were recognized in gyrA
nd parC QRDR of 64 ciproﬂoxacin resistant, 63 levoﬂoxacin– Leu (TTG) –
Asn (AAC) Leu (TTG) –
resistant and 1 levoﬂoxacin intermediate isolates, as described
in Table 2. The total mutations found in these isolates were
classiﬁed into 4 distinct groups according to the pattern of
amino acid alteration. Group I: isolates contained single muta-
tion Thr-83 → Ile in gyrA. Group II: isolates contained one
mutation Thr-83 → Ile in gyrA and one mutation Ala-88 →Pro
in parC. Group III: Isolates contained one mutation Thr-83 →
Ile in gyrA and one mutation Ser-87 → Leu in parC. Group IV:
isolates contained two mutations Thr-83 → Ile and Asp-87 →
Asn in gyrA and one mutation Ser-87 → Leu in parC.
DNA sequences of QRDR gyrA showed Thr-83 → Ile substi-
tution for all 64 ciproﬂoxacin resistant isolates. Of 64 isolates,
20 (31.25%) had a mutation (Thr-83 → Ile) in gyrA alone (group
I). A double mutation in gyrA (Thr-83 → Ile and Asp-87 →
Asn) was detected in 5 of 64 isolates. Amino acid alteration
in the QRDR parC was observed in 44 (68.75%) of 64 isolates.
All of these isolates possessed additional mutations in gyrA.
No double mutations in parC were found. The Ser-87 → Leu
substitution was found in 31 (48.4%) of 64 isolates. Moreover,
the substitution of Pro for Ala-88 was observed in 8 (12.5%) of
64 isolates.
Correlation  between  ﬂuoroquinolones  MIC  and  QRDRs
mutations
The MIC values of ciproﬂoxacin and levoﬂoxacin for 64 resis-
tant isolates and their correlation with different types of
mutations in gyrA and parC genes are shown in Table 3.
As shown, ciproﬂoxacin MIC for isolates with a single gyrA
substitution (Thr-83 → Ile) ranged from 4–64 g/mL and for
levoﬂoxacin, the 4–32 g/mL range was observed. Isolates
with a single gyrA (Thr-83 → Ile) substitution and a sin-
gle parC substitution (Ala-88 → Pro or Ser-87 → Leu) had
ciproﬂoxacin MICs ranging from 8 to 128 or 16 to 256 g/mL
and levoﬂoxacin MICs varied from 8 to 64 or 8 to 256 g/mL.
Moreover, the isolates with double gyrA substitutions (Thr-
83 → Ile and Asp-87 → Asn) and a single parC substitution
(Ser-87 → Leu) had ciproﬂoxacin and levoﬂoxacin MICs ran-
ging from 32 to 256 g/mL. Our results showed that the two
concurrent mutations in gyrA and parC genes were associ-
ated with a higher level of ciproﬂoxacin and levoﬂoxacin MICs,
as compared to a single mutation in gyrA. (Geometric mean
MICs of ciproﬂoxacin, 29.34 (group 2) and 32 (group 3) ver-
sus 16.56 (group 1) g/mL, p < 0.05; geometric mean MICs of
levoﬂoxacin, 24.67 (group 2) and 28.6 (group 3) versus 14.42
(group 1) g/mL p < 0.05). Moreover, three concurrent muta-
tions in gyrA and parC genes were associated with a higher
level of ciproﬂoxacin and levoﬂoxacin MICs, as compared to
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Table 3 – Correlation of mutations in gyrA and parC genes and MICs distribution of ciproﬂoxacin and levoﬂoxacin.
Group No.  of isolates Antimicrobial
agents
No.  of isolates with MICs (g/mL)
0.5 1 2 4 8 16 32 64 128 256
I
20
Ciproﬂoxacin 2  2 10 5 1
GyrA (83) Levoﬂoxacin 1  4 12 3
II
8
Ciproﬂoxacin 1 1 5 1
GyrA (83), ParC (88) Levoﬂoxacin 1 3 2 2
III
31
Ciproﬂoxacin 12 11 5 2 1
GyrA (83), ParC (87) Levoﬂoxacin 4 8 12 4 2 1IV
5
Ciproﬂoxacin 
GyrA (83 and 87), ParC (87) Levoﬂoxacin 
two concurrent mutations in gyrA and parC genes (Geometric
mean MICs of ciproﬂoxacin, 73.5 (group 4) versus 29.3 (group
2) g/mL, and 32 (group 3) g/mL p < 0.05; geometric mean
MICs of levoﬂoxacin, 64 (group 4) versus 24.6 (group 2) and
28.61 (group 3) g/mL p < 0.05) or single mutation in gyrA. (Geo-
metric mean MICs of ciproﬂoxacin, 73.51 (group 4) versus 16.56
(group 1) g/mL, p < 0.05; geometric mean MICs of levoﬂoxacin,
64 (group 4) versus 14.42 (group 1) g/mL p < 0.05).
Discussion
Fluoroquinolones such as ciproﬂoxacin and levoﬂoxacin are
an important class of antibiotics for the treatment of P. aeru-
ginosa infections.26 However, P. aeruginosa rapidly becomes
resistant to these drugs during antibiotic therapy.15 The princi-
ple mechanism of ﬂuoroquinolones resistance in P. aeruginosa
involves mutations in the genes of DNA gyrase and topoiso-
merase IV.18
In the present study, the alteration of Thr-83 to Ile in
gyrA was found in all ciproﬂoxacin and levoﬂoxacin resis-
tant P. aeruginosa isolates. Moreover, a double concomitant
mutation in gyrA (Thr-83 → Ile and Asp-87 → Asn) was
observed in ﬁve ciproﬂoxacin and levoﬂoxacin resistant
isolates. More  noteworthy, the MIC  values of tested ﬂuoro-
quinolones among these isolates were signiﬁcantly higher.
However, no amino acid change was detected in ciproﬂoxacin
susceptible, levoﬂoxacin susceptible and ciproﬂoxacin inter-
mediate isolates. So Thr-83 → Ile was shown to be the
chief mechanism of ﬂuoroquinolones resistance. This was
consistent with the results of other studies.26,28–30 Further-
more, the amino acid sequences analysis in the QRDR of
parC showed that more  than half of ciproﬂoxacin and levo-
ﬂoxacin resistant isolates had an alteration in parC and the
Ser-87 → Leu substitution was the predominant amino acid
change (48.4%). Lee et al.18 and Mouneimne et al.16 have
previously reported this amino acid change in 35.9% and
25% of the ciproﬂoxacin resistant isolates, respectively. Also,
another alteration in parC, Ala-88 → Pro substitution, was
highly frequent in our isolates, in comparison to the results
of Akasaka et al.,17 and Sekiguchi et al.31 They found this
amino acid change only in one of all studied isolates. More
importantly, this substitution was observed generally among
high level ciproﬂoxacin resistant isolates suggested to be
responsible for ﬂuoroquinolone resistance. However, we did2 1 1 1
2 1 2
not detect amino acid alteration at positions Pro-83, Gly-85,31
Glu-91 and Leu-9517 in parC, as reported in the previous stud-
ies.
Based on the analysis of sequencing results, all of the
isolates with parC mutation had one or two mutations in
gyrA. This observation conﬁrmed that the DNA gyrase was
the primary target for ﬂuoroquinolone resistance in the
clinical isolates of P. aeruginosa.  However, isolates that had
double mutation in gyrA and parC had higher ciproﬂoxacin
and levoﬂoxacin MICs than those with a single mutation
in gyrA, thereby suggesting that alteration in parC occurred
after gyrA, leading to higher level ﬂuoroquinolone resis-
tance in P. aeruginosa.  Moreover, the addition of a second
gyrA alteration to gyrA and parC mutations had a signif-
icant effect on ciproﬂoxacin and levoﬂoxacin MICs. Our
results suggested that there could be a correlation between
the number of gyrA and parC alterations and the level
of ﬂuoroquinolone resistance. This has been reported by
Lee et al.18 for the clinical isolates of P. aeruginosa.  Dif-
ferences in the MICs of ciproﬂoxacin and levoﬂoxacin for
isolates had a single alteration in QRDR of gyrA with
or without an alteration in QRDR of parC, revealing that
other resistance factors were involved in ﬂuoroquinolone
resistance. Mechanisms such as overexpression of efﬂux
pumps (MexAB-OprM32,33 MexCD-OprJ,28 MexEF-OprN21 and
MexXY-OprM34) and mutation in gyrB and parE have been
described for ﬂuoroquinolone resistance in P. aeruginosa.17,18
However, the impact of these mechanisms on MICs of
ciproﬂoxacin and levoﬂoxacin can be clariﬁed by further stud-
ies.
To conclude, mechanisms other than mutations in gyrA
and parC (such as active efﬂux pumps, alterations in gyrB,
parE or innate impermeability of the membrane) may con-
tribute to the level of ﬂuoroquinolone resistance in the clinical
isolates of P. aeruginosa,  but a single amino acid alteration,
Thr-83 → Ile, in gyrA, is sufﬁcient to cause clinically important
levels of resistance to ﬂuoroquinolones, and the simul-
taneous presence of mutation in parC (Ser-87 → Leu or
Ala-88 → Pro) mediates signiﬁcantly higher level ﬂuoro-
quinolone resistance.Finally, our results revealed that the mutations in gyrA and
parC were the main mechanism of ﬂuoroquinolone resistance
among the clinical isolates of P. aeruginosa in Tabriz, Iran. To
the best of our knowledge, this study is the largest analysis of
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